X

Trial Profile

A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NVL 330 (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; First in man
Acronyms HEROEX-1
Sponsors Nuvalent

Most Recent Events

13 Jan 2025 According to a Nuvalent media release, the company to progress this trial in 2025.
22 Jul 2024 According to a Nuvalent media release, the company announced the initiation of HEROEX-1, its Phase 1a/1b clinical trial evaluating NVL-330, for pre-treated patients with HER2-altered non-small cell lung cancer (NSCLC).
22 Jul 2024 Status changed from planning to recruiting, according to a Nuvalent media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com